Gary Clark: Unfiltered

After a period of limited availability, the Ellipsys Vascular Access System is set for a 2026 relaunch, promising a less invasive option for dialysis patients.

The hit craft beer brand and Skybound Entertainment team up for a new fighting game, blending IPAs with exclusive in-game content. Is this the future?

At eMerge Americas 2026, Nividous will demo its single-platform solution for orchestrating AI, aiming to solve widespread enterprise integration chaos.

Canals' new end-to-end AI platform promises radical efficiency for distributors. But what are the real-world impacts on jobs, data, and integration?

Evolveum unveils midPilot, an AI to fix slow IGA onboarding, as firms flee proprietary tech for open-source control and digital sovereignty.

A stark new benchmark study reveals poor survival in late-stage GvHD, just as MaaT Pharma’s microbiome therapy shows dramatically better outcomes.

With FDA approval, soaring revenues, and game-changing clinical data, InspireMD prepares to spotlight its CGuard Prime stent for investors this April.

For the first time, JETRO leads a delegation of Japanese industrial leaders to Miami, seeking innovation in mobility, manufacturing, and energy.

Oral care brand Boka is now in all 4,500 Walmart stores, marking a major moment for fluoride-free toothpaste and science-backed wellness.

The pharma giant expands its collaboration with OpenProtein.AI, integrating advanced AI to accelerate the creation of new drugs for cancer and autoimmune diseases.

In a strategic move to dominate the future of warfare, Red Cat Holdings has acquired Apium Swarm Robotics, deepening its role in a new defense tech race.

Amid a regional energy crisis, Egypt imposes strict conservation rules on citizens while exempting tourist zones to safeguard its vital economic lifeline.

A 78-year-old family business, Bender Plumbing Supply, joins a growing regional platform, reshaping the Northeast's competitive HVAC and plumbing market.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

A gene expression test is changing melanoma care by providing risk data beyond traditional staging, enabling more tailored treatment for patients.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

A privately funded $200M expansion aims to bring 10-gigabit internet to over 25 California cities, shaking up the state's telecom landscape.

A US firm is bringing embryo screening for chronic diseases to major IVF networks, sparking debate on the future of family planning and genetic health.

Real Messenger unveiled a major potential partnership, but its non-binding nature and market jitters reveal the high-stakes gamble facing the young company.